Dry Eye or MGD?
It’s time to change your outlook on dry eye.
There are around 30 million individuals in the United States and more than 300 million overall who have been determined to have dry eye. People suffering with dry eye have gotten to be subject to drops or other treatment techniques that only offer temporary alleviation of symptoms. This has been because of an absence of understanding that the underlying problem of most dry eye (86%) is currently known to be an interminable and dynamic condition, Meibomian Gland Dysfunction or MGD.
MGD happens when the meibomian glands in the eyelids that create the defensive slick layer of the tear film become blocked. These organs can become blocked after some time and can no longer create the necessary oils required for solid tears. This blockage brings about fast dissipation of your tears and lead to irritation, discomfort and if not treated, gland dropout.
A series of tests will be performed to determine if you have MGD. This can include a LipiView® tear film and gland imaging and a meibomian gland evaluation. Knowing what is causing your Dry Eye will help your doctor determine the best treatment option.
Now, with the breakthrough LipiFlow® technology, it’s possible to directly treat the root cause of MGD.
Treating MGD with LipiFlow
LipiFlow ® is a new treatment for dry eye that restores the lipid layer of the tear film, so the tears function better. While there are multiple choices available for treating MGD, LipiFlow is the only FDA-approved treatment for removing gland blockages and restoring gland function. Developed by TearScience, the sterile lid warmer and eyecup apply a combination of heat and pressure to the eyes for less than 15 minutes at a time, under constant monitoring by an eye doctor. The procedure is not painful, and enables the tear glands to secrete good quality tears, and is done in the comfort of your optometrist’s office.